B cells in systemic sclerosis: A possible target for therapy

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

“…К ним в первую очередь отно-сится ритуксимаб (РТМ), представляющий собой химер-ные моноклональные антитела к CD20-антигену, локали-зующемуся на мембране В-клеток, которые вызывают де-плецию (истощение) В-клеток в кровяном русле и в тка-нях [7][8][9]. Данные многочисленных экспериментальных и клинических исследований теоретически обосновыва-ют целесообразность применения РТМ для лечения мно-гих аутоиммунных заболеваний, в первую очередь ревма-тических [10][11][12][13]. В настоящее время РТМ зарегистриро-ван для лечения ревматоидного артрита (РА) [14] и сис-темных некротизирующих васкулитов, связанных с син-тезом антинейтрофильных цитоплазматических аутоан-тител (АНЦА-СВ) [15].…”

Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature

“…Since 1999 anecdotal observations followed by two pilot studies showed the efficacy and safety of anti-CD20 monoclonal antibody (rituximab) treatment in patients with cryoglobulinemic vasculitis, often resistant or intolerant to other therapies [9][10][11][12]. The safety and efficacy of this drug have been reported in various vasculitides and other systemic autoimmune diseases [13][14][15][16][17][18][19][20][21][22][23]. The usefulness of monoclonal antibodies directed to CD20 antigen, a trans membrane protein expressed on pre-B lymphocytes and mature B lymphocytes, on both cutaneous and visceral organ involvement of MCs, including low grade B-cell lymphoma, has been reported by various Authors, generally referred to small patients' series [24][25][26][27][28][29][30][31].…”

Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases

“…Several clinical studies have demonstrated the substantial impact of rituximab for treatment of various systemic autoimmune diseases [1][2][3][4][5][6][7][8][10][11][12][13][14][15][16][17]. Evidence of therapeutic effect is also mounting for numerous autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's granulomatosis and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, idiopathic thrombocytopenic purpura, multiple sclerosis and Sjogren's syndrome [4,7,[12][13][14][15].…”

“…It is, however, likely to be a combination of antibodydependant cell-mediated cytotoxicity, complement-mediated lysis, growth inhibition and apoptosis. In vivo experiments using a mouse model of immunotherapy suggest that the most important mechanism of action is via antibody-dependant cell-mediated cytotoxicity [1][2][3][4][5][6]. The mechanisms do, however, work in a complex manner.…”